|

Abatacept Clinical Trials

5 actively recruiting trials across 4 locations

▼ -1 trial since August 2026

Also known as: Orencia

Pipeline

Early 1: 1Phase 2: 1Phase 3: 2Phase 2/3: 1

Top Sponsors

  • Duke University2
  • University of Nebraska1
  • NYU Langone Health1
  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology1

Indications

  • Arthritis3
  • Cancer2
  • Rheumatic Disease1
  • Polyarticular Course Juvenile Idiopathic Arthritis (JIA)1
  • Acute Lymphoblastic Leukemia, Relapse1

Other1 trial

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Phase 2/3

San Francisco, California1 trial

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

University of California San Francisco Pediatric Rheumatology

Phase 3

Omaha, Nebraska1 trial

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska Medical Center

Phase 3

New York, New York1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Durham, North Carolina1 trial

HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT

Duke University Health System

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.